Moderna Finishes Initial Data Collection in Coronavirus Vaccine Trial; Results Could Be Published Soon
Moderna (NASDAQ: MRNA) is now very close to publishing the first results of the crucial late-stage clinical trial for mRNA-1273, the company's COVID-19 vaccine candidate.
The company revealed in a press release that it has completed the case accrual (i.e., finalized the collection of data) for the first interim analysis of mRNA-1273's phase 3 trial. Moderna's candidate is one of the few that has advanced to late-stage testing. It added that it is preparing the data for submission to the National Institutes of Health's (NIH) independent Data and Safety Monitoring Board for review and subsequent recommendation.
Moderna anticipates that it will be able to announce the results by the end of this month.
Source Fool.com
